Antibody developability assessment

Flag developability risks before ordering antibodies

Screen a set of antibody or nanobody candidates for surface patches, viscosity, polyreactivity, aggregation, solubility and humanness, then hand your team one table of flags before any gene is ordered.

Trusted by 16,500+ researchers and published in

  1. Number and model the domains

    Number the variable domains so CDRs are read the same way across candidates, and predict a structure for the checks that need one. ANARCII does the numbering, and ImmuneBuilder models antibodies and nanobodies.

  2. Profile surface patches

    TAP2 and TNP compare CDR length and surface patches with clinical-stage antibodies and nanobodies. DeepSP predicts aggregation and charge descriptors from sequence, and Aggrescan3D scores aggregation per residue on a structure.

  3. Predict viscosity and polyreactivity

    Both classifiers take a paired Fv sequence and return a low or high call. DeepViscosity predicts viscosity at 150 mg/mL and PolyXpert predicts polyreactivity. Neither replaces a measured assay.

  4. Check solubility, humanness and liabilities

    NetSolP and Protein-Sol predict solubility from sequence, BioPhi scores humanness, and the glycosylation finder lists N-linked sequons, including those in CDRs.

Run antibody developability assessment on ProteinIQ

FAQs

AI answers from our docs. No sign-in needed.

Focus on research, not infrastructure

Start free with 200 credits a month and no installs. Upgrade when your project needs more compute.